PVLA Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -- compared to Palvella Therapeutics, Inc.'s net margin of --. Palvella Therapeutics, Inc.'s return on equity of -101.06% beat CEL-SCI Corp.'s return on equity of -230.36%.

Palvella Therapeutics, Inc. has a consensus price target of $182.57, signalling upside risk potential of 80.51%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 718.88%. Given that CEL-SCI Corp. has higher upside potential than Palvella Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Palvella Therapeutics, Inc..

Palvella Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Palvella Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palvella Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Palvella Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Palvella Therapeutics, Inc.'s net income of -$11.3M is lower than CEL-SCI Corp.'s net income of -$6.1M. Notably, Palvella Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palvella Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Inhibrx Biosciences, Inc. has a net margin of -- compared to Palvella Therapeutics, Inc.'s net margin of -2204.15%. Palvella Therapeutics, Inc.'s return on equity of -101.06% beat Inhibrx Biosciences, Inc.'s return on equity of -151.49%.

Palvella Therapeutics, Inc. has a consensus price target of $182.57, signalling upside risk potential of 80.51%. On the other hand Inhibrx Biosciences, Inc. has an analysts' consensus of $12.00 which suggests that it could fall by -84.86%. Given that Palvella Therapeutics, Inc. has higher upside potential than Inhibrx Biosciences, Inc., analysts believe Palvella Therapeutics, Inc. is more attractive than Inhibrx Biosciences, Inc..

Palvella Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inhibrx Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Palvella Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inhibrx Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palvella Therapeutics, Inc. pays -- of its earnings as a dividend. Inhibrx Biosciences, Inc. pays out -- of its earnings as a dividend.

Palvella Therapeutics, Inc. quarterly revenues are --, which are smaller than Inhibrx Biosciences, Inc. quarterly revenues of --. Palvella Therapeutics, Inc.'s net income of -$11.3M is higher than Inhibrx Biosciences, Inc.'s net income of -$35.3M. Notably, Palvella Therapeutics, Inc.'s price-to-earnings ratio is -- while Inhibrx Biosciences, Inc.'s PE ratio is 0.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palvella Therapeutics, Inc. is -- versus 861.92x for Inhibrx Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ligand Pharmaceuticals, Inc. has a net margin of -- compared to Palvella Therapeutics, Inc.'s net margin of 10.18%. Palvella Therapeutics, Inc.'s return on equity of -101.06% beat Ligand Pharmaceuticals, Inc.'s return on equity of 5.72%.

Palvella Therapeutics, Inc. has a consensus price target of $182.57, signalling upside risk potential of 80.51%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $243.44 which suggests that it could grow by 24.74%. Given that Palvella Therapeutics, Inc. has higher upside potential than Ligand Pharmaceuticals, Inc., analysts believe Palvella Therapeutics, Inc. is more attractive than Ligand Pharmaceuticals, Inc..

Palvella Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.587%.

Palvella Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palvella Therapeutics, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Palvella Therapeutics, Inc. quarterly revenues are --, which are smaller than Ligand Pharmaceuticals, Inc. quarterly revenues of $115.5M. Palvella Therapeutics, Inc.'s net income of -$11.3M is lower than Ligand Pharmaceuticals, Inc.'s net income of $117.3M. Notably, Palvella Therapeutics, Inc.'s price-to-earnings ratio is -- while Ligand Pharmaceuticals, Inc.'s PE ratio is 93.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palvella Therapeutics, Inc. is -- versus 15.29x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pelthos Therapeutics, Inc. has a net margin of -- compared to Palvella Therapeutics, Inc.'s net margin of -219.26%. Palvella Therapeutics, Inc.'s return on equity of -101.06% beat Pelthos Therapeutics, Inc.'s return on equity of -241.95%.

Palvella Therapeutics, Inc. has a consensus price target of $182.57, signalling upside risk potential of 80.51%. On the other hand Pelthos Therapeutics, Inc. has an analysts' consensus of $59.80 which suggests that it could grow by 119.85%. Given that Pelthos Therapeutics, Inc. has higher upside potential than Palvella Therapeutics, Inc., analysts believe Pelthos Therapeutics, Inc. is more attractive than Palvella Therapeutics, Inc..

Palvella Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pelthos Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Palvella Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pelthos Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palvella Therapeutics, Inc. pays -- of its earnings as a dividend. Pelthos Therapeutics, Inc. pays out -- of its earnings as a dividend.

Palvella Therapeutics, Inc. quarterly revenues are --, which are smaller than Pelthos Therapeutics, Inc. quarterly revenues of $7.4M. Palvella Therapeutics, Inc.'s net income of -$11.3M is higher than Pelthos Therapeutics, Inc.'s net income of -$16.2M. Notably, Palvella Therapeutics, Inc.'s price-to-earnings ratio is -- while Pelthos Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palvella Therapeutics, Inc. is -- versus 9.28x for Pelthos Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.